 |
News releases
Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.
To automatically receive future news releases, please go to the News
subscription service page.
2013
- 2012
- 2011
- 2010
- 2009
- [2008]
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
(click to view the full text)
|
December 11, 2008
Æterna Zentaris Completes Patient Recruitment for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia |
December 4, 2008
Æterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference |
December 3, 2008
Æterna Zentaris Closes Sale of Cetrotide® Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners |
November 13, 2008
Æterna Zentaris Reports Third Quarter 2008 Financial and Operating Results |
November 12, 2008
Æterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008 |
November 12, 2008
Æterna Zentaris Agrees to Sell Cetrotide® Royalty Stream for
$52.5 Million to Cowen Healthcare Royalty Partners |
November 3, 2008
Æterna Zentaris Reaches 2nd Stage of Patient Recruitment for
Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 |
October 28, 2008
Æterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference |
October 24, 2008
Æterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price |
October 2, 2008
Æterna Zentaris Reaches 2nd Stage of Patient Recruitment for
Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 |
October 1, 2008
Æterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia |
September 25, 2008
Æterna Zentaris to Present at BioContact Quebec on October 2, 2008 |
September 17, 2008
Æterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference |
August 12, 2008
Æterna Zentaris Announces Appointment of Prof. Jürgen Engel, Ph.D. as New President and CEO |
August 12, 2008
Æterna Zentaris Reports Second Quarter 2008 Financial and Operating Results |
August 6, 2008
Æterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008 |
July 31, 2008
Æterna Zentaris to Present at Upcoming BMO Capital Markets 2008 Focus on Healthcare Conference and 28th Annual Canaccord Adams Global Growth Conference |
June 27, 2008
Æterna Zentaris Sells Quebec City Building for $7.1 million |
May 15, 2008
Æterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting |
May 14, 2008
Æterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia |
May 13, 2008
Æterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal |
May 7, 2008
Æterna Zentaris Reports First Quarter 2008 Financial and Operating Results |
May 1, 2008
Æterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008 |
April 30, 2008
Æterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan |
April 22, 2008
Æterna Zentaris’ Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia |
April 15, 2008
Æterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia |
April 11, 2008
Æterna Zentaris Announces Changes to its Management Team |
April 1, 2008
Æterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights |
March 26, 2008
Æterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia |
March 5, 2008
Æterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results |
March 3, 2008
Æterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights |
February 29, 2008
Æterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs |
February 28, 2008
Æterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008 |
February 19, 2008
Æterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California |
February 12, 2008
Æterna Zentaris Reports First Patients Treated with
Anti-Cancer Compound AEZS-108 in Phase 2 Trial
in Ovarian and Endometrial Cancers
|
 |
 |
